Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency

It has been 9 years since Mr. Jesse Gelsinger died from complications of vector administration in a liver gene therapy trial of research subjects with a deficiency of ornithine transcarbamylase (OTCD). This study was performed at the Institute for Human Gene Therapy of the University of Pennsylvania...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular genetics and metabolism 2009-04, Vol.96 (4), p.151-157
1. Verfasser:	Wilson, James M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trial Clinical Trials as Topic Clinical Trials, Phase I as Topic Gene therapy Genetic Therapy Humans Ornithine Carbamoyltransferase Deficiency Disease - genetics Ornithine Carbamoyltransferase Deficiency Disease - therapy Ornithine transcarbamylase deficiency
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!